Virax Biolabs Group (NASDAQ:VRAX) Stock Price Down 9.1% – What’s Next?

Virax Biolabs Group Limited (NASDAQ:VRAX)’s stock price fell 9.1% during trading on Monday. The stock traded as low as $1.10 and last traded at $1.10. Approximately 24,229 shares traded hands during trading, a decline of 88% from the average session volume of 202,825 shares. The stock had previously closed at $1.21.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on VRAX. Wall Street Zen upgraded shares of Virax Biolabs Group from a “sell” rating to a “hold” rating in a report on Monday, July 13th. Weiss Ratings restated a “sell (e+)” rating on shares of Virax Biolabs Group in a report on Friday, October 2nd. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $25.00.

Virax Biolabs Group Stock Performance

The company has a 50-day moving average of $2.07 and a two-hundred day moving average of $3.88.

Virax Biolabs Group Company Profile

Virax Biolabs Group Limited (NASDAQ: VRAX) is a biotechnology company focused on the prevention, detection and diagnosis of viral diseases. The company develops and commercializes diagnostic technologies designed to help identify infections and evaluate immune responses to viral pathogens.

Its product portfolio has included Virax Immune, a T-cell-based test intended to assess cellular immune responses to SARS-CoV-2 and other viral threats. Virax Biolabs has also pursued rapid testing and diagnostic solutions for infectious diseases, with offerings marketed through healthcare, laboratory and distribution channels.

Founded in the United Kingdom, Virax Biolabs serves international markets and has focused on expanding access to viral testing and immune-profiling technologies.